Business
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
ZURICH, Nov. 6, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for
About this update from Newcelx Ltd.
[{"type":"text","content":"\n ZURICH, Nov. 6, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) (\"NewcelX\" or the \"Company\"), a biotechnology company advancing transformative therapies for neurodegenerative and metabolic diseases, today announced that Professor Tamir Ben-Hur, MD, PhD, a renowned neurologist and long-time scientific advisor of Kadimastem Ltd., will join the Company's Scientific Advisory Board.\n \n \n \n Prof. Ben-Hur, a Professor of Neurology at Hadassah University Medical Center and the Hebrew University of Jerusalem, is widely recognized as a global expert in neuroimmunology and stem-cell-based regenerative medicine.\n \n Prof. Tamir Ben-Hur said, \"It is an honor to join this scientific journey and NewcelX as a global biotech advancing regenerative and neuroscience-based therapies. I am excited to see scientific success, expecting that by combining cell therapy and central nervous system drug innovation, NewcelX will deliver meaningful therapeutic advances for patients worldwide.\"\n \n Prof. Michel Revel, Chief Scientific Officer of NewcelX, added, \"Prof. Ben-Hur's involvement with NewcelX brings deep clinical expertise and a shared commitment to advancing innovative cell therapies that address the root causes of neurodegenerative disease.\"\n \n Ronen Twito, Executive Chairman and Chief Executive Officer of NewcelX, stated, \"We are honored that Prof. Ben-Hur will join us in NewcelX. His decision reflects confidence in our science and our mission to build a global biotechnology company delivering breakthrough therapies for ALS and diabetes.\"\n The commitment of Prof. Ben-Hur to join the NewcelX Scientific Advisory Board represents a strong endorsement of the Merger and the scientific foundation on which NewcelX is being built — uniting Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.\n \n About NewCelX Ltd.\n \n NewcelX Ltd. (Nasdaq: NCEL) is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The Company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as ALS and Type 1 Diabetes. NewcelX is headquartered in Zurich, Switzerland, with resea...